Artelo Biosciences, Inc. — FY 2022 Form 10-K
Reporting period: Year ended December 31, 2022. The company changed its fiscal year-end from August 31 to December 31; accordingly, its audited comparative period is the four months ended December 31, 2021. Management also presents an unaudited full-calendar-year 2021 comparison. Amounts below are in U.S. dollars.
Business context
Artelo is a clinical-stage biopharmaceutical company developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system. It has no approved products and has generated no revenue. Its lead clinical program, ART27.13, is being studied for cancer-related anorexia; ART26.12 and ART12.11 remain preclinical.
Financial results and liquidity
| Metric | FY 2022 | FY 2021, unaudited |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4.324 million | $3.784 million |
| General and administrative expense | $5.963 million | $5.633 million |
| Total operating expenses | $10.287 million | $9.417 million |
| Net loss | $10.083 million | $9.407 million |
| Operating cash used | $8.008 million | $6.938 million |
Operating expenses rose about 9% and net loss about 7% year over year. Management attributed the expense increase mainly to CAReS trial spending and higher payroll, director compensation, and stock-based compensation. Gross margin is not applicable because the company had no revenue.
At December 31, 2022, cash and cash equivalents were $6.888 million, trading securities $9.150 million, and available-for-sale securities $1.495 million. Current assets totaled $18.322 million; current liabilities were $0.998 million, yielding working capital of $17.324 million. Total liabilities were $1.021 million, primarily accounts payable/accruals and lease obligations; the filing reports no material borrowing debt. Stockholders’ equity was $19.403 million.
Cash and cash equivalents decreased $5.274 million during 2022. Investing activities provided $2.958 million, largely reflecting net security sales; there were no financing cash flows in 2022. The company reported a $10.319 million comprehensive loss. The filing does not provide a clear operating margin measure; operating loss was $10.287 million.
Material changes and financing
- Cash and current assets fell from $12.162 million and $24.609 million, respectively, at December 31, 2021, as liquid resources funded operations; current liabilities remained approximately $1.0 million.
- Artelo raised $18.262 million net in an equity offering in November 2021. In May 2022, it entered a 36-month equity purchase facility with Lincoln Park for up to $20 million, but had made no sales under it by year-end. The facility is available at the company’s option and is not assured funding.
- The company effected a 1-for-15 reverse stock split in August 2022 and regained Nasdaq minimum-bid-price compliance in August 2022.
- Stock-based compensation was $2.458 million in 2022, versus $2.4 million in the unaudited calendar 2021 comparison.
Outlook, risks, and unusual items
- Management estimated existing resources would support planned operations into the second half of 2024, but stated that further funding will be required to continue beyond that period. The filing nevertheless identifies substantial doubt about the company’s ability to continue as a going concern.
- Management anticipated starting the Phase 2a portion of the ART27.13 CAReS trial in the first half of 2023, following completion of an additional higher-dose cohort. The filing describes prior COVID-related minor delays.
- ART26.12 was in regulatory-enabling work; first-in-human studies were anticipated around mid-2024, subject to study resources, supply availability, pandemic impacts, and regulatory review. These are forward-looking estimates, not commitments.
- Key risks include clinical failure or delay, patient enrollment and supply constraints, dependence on third-party research and manufacturing providers, need for additional capital and possible dilution, licensing and patent obligations, controlled-substance regulation, competition, and the uncertain effects of UK R&D tax-credit changes from 2023–2024.
- UK R&D tax credits currently reduce development costs; the filing warns relief may diminish, including for certain activity outside the UK from April 2024. The company also has potential milestone and royalty obligations under its ART27.13 and Stony Brook licenses.
- The independent auditor issued an unqualified opinion on the financial statements and reported no critical audit matters. The auditor did not attest to internal control over financial reporting; management stated that disclosure controls and internal control were effective.
Important facts for investors to verify
- Current cash, marketable-security balances, actual quarterly cash burn, and the runway implied by management’s second-half-2024 estimate.
- Whether and on what terms Artelo uses the Lincoln Park facility or secures other financing, including resulting dilution.
- CAReS enrollment, dose selection, Phase 2a commencement, and any updated trial results or timelines.
- Progress and funding needs for ART26.12 regulatory-enabling studies and ART12.11 development priorities.
- UK R&D tax-credit eligibility and the timing and amount of license milestones, royalties, and other development commitments.
- Reconcile the filing’s stated substantial going-concern doubt with management’s projected operating runway, and monitor subsequent filings for updated liquidity disclosures.